Breaking: Cowen & Co. Reconfirms $63.0 Price Target On Alkermes (NASDAQ:ALKS) Shares, Reconfirms Their Original “Buy” Rating

January 16, 2018 - By Richard Conner

 Breaking: Cowen & Co. Reconfirms $63.0 Price Target On Alkermes (NASDAQ:ALKS) Shares, Reconfirms Their Original

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.08, from 1.12 in 2017Q2. It dived, as 32 investors sold Alkermes plc shares while 64 reduced holdings. 32 funds opened positions while 68 raised stakes. 144.69 million shares or 1.07% more from 143.16 million shares in 2017Q2 were reported.

Baker Bros Limited Partnership reported 150,251 shares. Moreover, Caisse De Depot Et Placement Du Quebec has 0% invested in Alkermes plc (NASDAQ:ALKS). Rhenman & Partners Asset Management Ab holds 145,000 shares or 0.94% of its portfolio. Fred Alger owns 14,500 shares. Td Ltd Co invested in 20 shares. Primecap Mgmt Co Ca reported 13.11M shares. Moreover, Winfield Associates Inc has 0% invested in Alkermes plc (NASDAQ:ALKS) for 40 shares. Raymond James Financial Service Advsrs Inc has 15,033 shares for 0% of their portfolio. Atika Capital Ltd Co holds 0.31% of its portfolio in Alkermes plc (NASDAQ:ALKS) for 21,000 shares. Cap Fund Mngmt Sa has invested 0.03% in Alkermes plc (NASDAQ:ALKS). Daiwa Sb Investments stated it has 2,865 shares or 0.05% of all its holdings. Aperio Group Ltd Liability Company accumulated 20,981 shares. Putnam Invs Lc reported 148,986 shares. Bancorporation Of Montreal Can has 6,853 shares for 0% of their portfolio. State Of New Jersey Common Pension Fund D reported 70,000 shares.

Alkermes (NASDAQ:ALKS) Rating Reaffirmed

Recently, In an analyst note shared with investors and clients on Friday, 27 October, Alkermes (NASDAQ:ALKS) shares have had their “Buy” Rating reconfirmed by expert analysts at Cowen & Co., who currently has a $63.0 target price on company. This target by Cowen & Co. gives the possibile upside of 10.84 % from the current stock price.

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.08, from 1.12 in 2017Q2. It dived, as 32 investors sold Alkermes plc shares while 64 reduced holdings. 32 funds opened positions while 68 raised stakes. 144.69 million shares or 1.07% more from 143.16 million shares in 2017Q2 were reported.

Baker Bros Limited Partnership reported 150,251 shares. Moreover, Caisse De Depot Et Placement Du Quebec has 0% invested in Alkermes plc (NASDAQ:ALKS). Rhenman & Partners Asset Management Ab holds 145,000 shares or 0.94% of its portfolio. Fred Alger owns 14,500 shares. Td Ltd Co invested in 20 shares. Primecap Mgmt Co Ca reported 13.11M shares. Moreover, Winfield Associates Inc has 0% invested in Alkermes plc (NASDAQ:ALKS) for 40 shares. Raymond James Financial Service Advsrs Inc has 15,033 shares for 0% of their portfolio. Atika Capital Ltd Co holds 0.31% of its portfolio in Alkermes plc (NASDAQ:ALKS) for 21,000 shares. Cap Fund Mngmt Sa has invested 0.03% in Alkermes plc (NASDAQ:ALKS). Daiwa Sb Investments stated it has 2,865 shares or 0.05% of all its holdings. Aperio Group Ltd Liability Company accumulated 20,981 shares. Putnam Invs Lc reported 148,986 shares. Bancorporation Of Montreal Can has 6,853 shares for 0% of their portfolio. State Of New Jersey Common Pension Fund D reported 70,000 shares.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

Among 13 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Alkermes has $85 highest and $35 lowest target. $64.25’s average target is 13.04% above currents $56.84 stock price. Alkermes had 34 analyst reports since September 1, 2015 according to SRatingsIntel. Credit Suisse maintained the stock with “Outperform” rating in Friday, October 27 report. The firm earned “Buy” rating on Friday, October 20 by Mizuho. The stock of Alkermes plc (NASDAQ:ALKS) earned “Buy” rating by Evercore on Thursday, May 26. The company was maintained on Tuesday, November 28 by Credit Suisse. Barclays Capital maintained Alkermes plc (NASDAQ:ALKS) on Friday, July 29 with “Overweight” rating. As per Friday, January 22, the company rating was maintained by UBS. The rating was maintained by Leerink Swann on Friday, October 21 with “Outperform”. Cowen & Co downgraded it to “Market Perform” rating and $50 target in Thursday, January 21 report. Jefferies maintained the shares of ALKS in report on Tuesday, September 26 with “Buy” rating. The stock has “Neutral” rating by JP Morgan on Thursday, January 21.

The stock decreased 3.19% or $1.87 during the last trading session, reaching $56.84. About 1.07 million shares traded or 6.88% up from the average. Alkermes plc (NASDAQ:ALKS) has risen 47.50% since January 16, 2017 and is uptrending. It has outperformed by 30.80% the S&P500.

Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on February, 21. They expect $-0.01 EPS, up 75.00 % or $0.03 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Alkermes plc for the previous quarter, Wall Street now forecasts -88.89 % EPS growth.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $8.74 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

More important recent Alkermes plc (NASDAQ:ALKS) news were published by: Prnewswire.com which released: “Alkermes’ Corporate Presentation to be Webcast at the 36th Annual JP Morgan …” on January 02, 2018, also Businesswire.com published article titled: “The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of …”, Livetradingnews.com published: “Alkermes Plc (NASDAQ:ALKS) Heffx Technical Analysis” on December 28, 2017. More interesting news about Alkermes plc (NASDAQ:ALKS) was released by: Businesswire.com and their article: “The Klein Law Firm Announces a Class Action Commenced on Behalf of Alkermes …” with publication date: December 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: